Xiaoban Xin focuses his practice on patent prosecution and portfolio development, strategy and due diligence. He has extensive experience preparing, prosecuting and evaluating patents in a broad range of technical areas in the life sciences sector, including biologics (e.g., antibodies, peptides, RNAs, etc.), gene editing (e.g., CRISPR-Cas), cell therapy, drug delivery vehicles, next generation sequencing and small molecules. He also has worked with medical devices, chemical engineering and materials, energy and clean tech, mechanical engineering and health IT.

Xiaoban reviews each client’s business and technology with a critical eye so he can bring a detailed understanding of the science at issue. He believes in partnering with his clients to formulate the patent strategy that best suits their business objectives. He regularly works with in-house counsel, senior management and technology transfer office managers, and often serves as the link between inventor and marketplace.

Xiaoban provides due diligence for commercial transactions, including evaluation of the strength, scope and potential of patents of prospective partners and competitors, as well as general diligence in support of investment or mergers and acquisitions projects.

Xiaoban has been extensively involved in prior art search and analysis, invalidity, non-infringement position development, and drafting briefs in support of patent litigation, including USPTO proceedings, and court and ITC litigations.

Prior to his legal career, Xiaoban gained extensive experience in biomedical research. Xiaoban holds a Ph.D. in cellular and molecular biology and completed a technology transfer fellowship with The National Institute of Allergy and Infectious Diseases at the National Institutes of Health, and a post-doctoral research fellowship with The Johns Hopkins University School of Medicine.

During his studies at George Washington University Law School, Xiaoban served as editor of the American Intellectual Property Law Association Quarterly Journal.

Xiaoban is fluent in Mandarin Chinese.